Myeloid antigen-presenting cell niches sustain antitumor T cells and license PD-1 blockade via CD28 costimulation.
Détails
Télécharger: 1-s2.0-S1535610821005596-main.pdf (11106.23 [Ko])
Etat: Public
Version: de l'auteur⸱e
Licence: Non spécifiée
Etat: Public
Version: de l'auteur⸱e
Licence: Non spécifiée
ID Serval
serval:BIB_4A546D8AF05A
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Myeloid antigen-presenting cell niches sustain antitumor T cells and license PD-1 blockade via CD28 costimulation.
Périodique
Cancer cell
ISSN
1878-3686 (Electronic)
ISSN-L
1535-6108
Statut éditorial
Publié
Date de publication
13/12/2021
Peer-reviewed
Oui
Volume
39
Numéro
12
Pages
1623-1642.e20
Langue
anglais
Notes
Publication types: Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
Publication Status: ppublish
Publication Status: ppublish
Résumé
The mechanisms regulating exhaustion of tumor-infiltrating lymphocytes (TIL) and responsiveness to PD-1 blockade remain partly unknown. In human ovarian cancer, we show that tumor-specific CD8 <sup>+</sup> TIL accumulate in tumor islets, where they engage antigen and upregulate PD-1, which restrains their functions. Intraepithelial PD-1 <sup>+</sup> CD8 <sup>+</sup> TIL can be, however, polyfunctional. PD-1 <sup>+</sup> TIL indeed exhibit a continuum of exhaustion states, with variable levels of CD28 costimulation, which is provided by antigen-presenting cells (APC) in intraepithelial tumor myeloid niches. CD28 costimulation is associated with improved effector fitness of exhausted CD8 <sup>+</sup> TIL and is required for their activation upon PD-1 blockade, which also requires tumor myeloid APC. Exhausted TIL lacking proper CD28 costimulation in situ fail to respond to PD-1 blockade, and their response may be rescued by local CTLA-4 blockade and tumor APC stimulation via CD40L.
Mots-clé
Antigen-Presenting Cells/metabolism, CD28 Antigens/metabolism, Humans, Immune Checkpoint Inhibitors/pharmacology, Immune Checkpoint Inhibitors/therapeutic use, Myeloid Cells/metabolism, Neoplasms/drug therapy, Neoplasms/immunology, Stem Cell Niche/genetics, CD28, CD40, CTLA-4, PD-1, TIL, dendritic cell, exhaustion, myeloid niche, ovarian, tumor
Pubmed
Web of science
Création de la notice
08/11/2021 10:25
Dernière modification de la notice
19/07/2024 6:11